GLUE

Monte Rosa Therapeutics, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$14.26

−$0.01−0.07%

Delayed · 2026-09-09T20:00:00.000Z · marketstack

1 of 47tracked managers hold this· Q2 2026

Aug 10, 2026$14.26

−$1.56−9.86%over 1M

Day range18% of range

$14.13$14.87

Session

Previous close: $14.27
Open: $14.28
Volume: 1.15M
Avg volume: -
Day high: $14.87
Day low: $14.13

Fundamentals

Visualize fundamentals and more

Market cap: 1.45B
P/E ratio: -
EPS (TTM): -$1.59
Dividend yield: -
Beta: 1.45
Shares outstanding: 101.48M

Source SEC EDGAR · 9/9/2026

Tracked investors

As of Q2 2026 · 72 days ago · next update ~14 Nov 2026· what moved this quarter, onMeasure

1 fund manager this platform follows disclosed a position here, from quarterly SEC filings up to 45 days old; a manager may have sold since without yet having to say so.

Stanley Druckenmiller
Duquesne Family Office
$7.2M
0.17%of book

Manager	Position	Share of their book	Last change
Stanley Druckenmiller Duquesne Family Office	$7.2M	0.17%

Share price, with each quarter a tracked manager’s position changed shaded across the range it traded in.

162024

now

Q2 '26

Hover a shaded quarter to see it moved. Who, and the range they traded in, is onBespoke

13F filings cover US-listed shares only (not cash, bonds, shorts, or private holdings) and are never a recommendation to do the same.

Risk factors, year on year

Item 1AMarch 2026 10-KMarch 2025as filed.

added: 41
dropped: 45
re-drafted: 41

Out of 302 passages in this year’s Item 1A.

New this year

• finalize our Phase 1 clinical trial for MRT-8102, our NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6;

85 more passages, included withBespoke

Recent activity

Sep 8Regulation FD disclosureCompany filing8-K

17 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Companies like Monte Rosa Therapeutics, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside GLUE.

MRNAModerna, Inc.
ALNYALNYLAM PHARMACEUTICALS, INC.
REGNREGENERON PHARMACEUTICALS, INC.
VRTXVERTEX PHARMACEUTICALS INC / MA
INSMINSMED Inc
ARGXARGENX SE

Ask about Monte Rosa Therapeutics, Inc.

The assistant answers from what GLUE has actually filed: 6 annual reports filed with the SEC, 13F positions from the 1 tracked investor who hold it and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from GLUE's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding Monte Rosa Therapeutics, Inc., and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

What an account lets you do with Monte Rosa Therapeutics, Inc.

Separate the decisions from the paperwork
Every Form 4 GLUE insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about Monte Rosa Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free accountSee what the paid plans add

Free, no card, and it does not expire.